ANGLE plc (AGL) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.385x

Based on the latest financial reports, ANGLE plc (AGL) has a cash flow conversion efficiency ratio of -0.385x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-4.50 Million ≈ $-547.76 USD) by net assets (GBX11.69 Million ≈ $1.42K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ANGLE plc (AGL) total market value for the company's overall valuation and market capitalisation.

ANGLE plc - Cash Flow Conversion Efficiency Trend (2001–2024)

This chart illustrates how ANGLE plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

ANGLE plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ANGLE plc ranked by their cash flow conversion efficiency. Explore earnings quality score of ANGLE plc to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Tap Global Group Plc
LSE:TAP
3.296x
Altona Rare Earths PLC
LSE:REE
-0.494x
Green Leaf Innovations Inc.
NASDAQ:GRLFD
N/A
DOLPHIN DRILL. A.S. NK 10
F:L33
N/A
CRISM Therapeutics Corporation
LSE:CRTX
-0.775x
Global Partner Acq Corp
NASDAQ:GPACU
0.297x
CORE ASSETS CORP.
F:5RJ
N/A
Trafalgar New Homes Plc
LSE:TRAF
-0.117x

Annual Cash Flow Conversion Efficiency for ANGLE plc (2001–2024)

The table below shows the annual cash flow conversion efficiency of ANGLE plc from 2001 to 2024. View ANGLE plc share price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 GBX18.44 Million
≈ $2.24K
GBX-13.45 Million
≈ $-1.64K
-0.729x -15.70%
2023-12-31 GBX22.94 Million
≈ $2.79K
GBX-14.46 Million
≈ $-1.76K
-0.630x -57.33%
2022-12-31 GBX40.06 Million
≈ $4.87K
GBX-16.05 Million
≈ $-1.95K
-0.401x -15.32%
2021-12-31 GBX40.33 Million
≈ $4.91K
GBX-14.01 Million
≈ $-1.70K
-0.347x -52.02%
2020-12-31 GBX34.34 Million
≈ $4.18K
GBX-7.85 Million
≈ $-954.87
-0.229x +27.02%
2019-12-31 GBX26.60 Million
≈ $3.24K
GBX-8.33 Million
≈ $-1.01K
-0.313x +17.22%
2019-04-30 GBX19.34 Million
≈ $2.35K
GBX-7.31 Million
≈ $-889.90
-0.378x +11.80%
2018-04-30 GBX15.88 Million
≈ $1.93K
GBX-6.81 Million
≈ $-828.82
-0.429x +48.85%
2017-04-30 GBX8.81 Million
≈ $1.07K
GBX-7.38 Million
≈ $-898.30
-0.838x +7.83%
2016-04-30 GBX5.24 Million
≈ $636.95
GBX-4.76 Million
≈ $-579.40
-0.910x -168.19%
2015-04-30 GBX10.09 Million
≈ $1.23K
GBX-3.42 Million
≈ $-416.36
-0.339x +16.30%
2014-04-30 GBX5.51 Million
≈ $671.02
GBX-2.23 Million
≈ $-271.93
-0.405x -97.56%
2013-04-30 GBX6.79 Million
≈ $825.71
GBX-1.39 Million
≈ $-169.38
-0.205x +16.39%
2012-04-30 GBX4.41 Million
≈ $536.08
GBX-1.08 Million
≈ $-131.53
-0.245x -37.30%
2011-04-30 GBX4.53 Million
≈ $551.54
GBX-810.00K
≈ $-98.55
-0.179x -61.09%
2010-04-30 GBX4.16 Million
≈ $505.67
GBX-461.00K
≈ $-56.09
-0.111x +46.35%
2009-04-30 GBX3.82 Million
≈ $464.91
GBX-790.00K
≈ $-96.12
-0.207x +34.06%
2008-04-30 GBX7.22 Million
≈ $878.59
GBX-2.26 Million
≈ $-275.46
-0.314x +71.32%
2007-04-30 GBX5.70 Million
≈ $693.16
GBX-6.23 Million
≈ $-757.65
-1.093x -303.88%
2006-04-30 GBX14.48 Million
≈ $1.76K
GBX-3.92 Million
≈ $-476.83
-0.271x 0.00%
2005-04-30 GBX14.48 Million
≈ $1.76K
GBX-3.92 Million
≈ $-476.83
-0.271x -5819.15%
2004-04-30 GBX10.99 Million
≈ $1.34K
GBX52.00K
≈ $6.33
0.005x +100.44%
2003-04-30 GBX546.00K
≈ $66.43
GBX-592.00K
≈ $-72.03
-1.084x +4.59%
2002-04-30 GBX909.00K
≈ $110.60
GBX-1.03 Million
≈ $-125.69
-1.136x -23.10%
2001-04-30 GBX1.30 Million
≈ $158.29
GBX-1.20 Million
≈ $-146.13
-0.923x --

About ANGLE plc

LSE:AGL UK Diagnostics & Research
Market Cap
$94.18K
GBX774.07 Million GBX
Market Cap Rank
#31515 Global
#1131 in UK
Share Price
GBX2.40
Change (1 day)
-9.43%
52-Week Range
GBX1.75 - GBX3.25
All Time High
GBX156.00
About

ANGLE plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis. It also provides Portrait+ C… Read more